Medications

Combined therapy makes headway for liver cancer

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...

Medications

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

New insights into the growth and spread of cancer cells

Cancer cells are characterized by their aggressiveness: they grow rapidly and spread to other parts of the body. To enable this, numerous mechanisms come into play, and one of them involves a protein called MYC, which activates ...

page 1 from 40